Suvorexant CAS 1030377-33-3

Khoom Qhia:

Khoom npe: suvorexant CAS TSIS: 1030377-33-3

Txhais:

[(7R) -4- (5-Chloro-1,3-benzoxazol-2-yl) -7-methyl-1,4-diazepan-1-yl] [5-methyl-2- (2H-1,2 , 3-triazol-2-yl) phenyl] methanone;

[(7R) -4- (5-chloro-1,3-benzoxazol-2-yl) -7-methyl-1,4-diazepan-1-yl] - [5-methyl-2- (triazol-2- yl) phenyl] methanone;

[(R) -4- (5-chlorobenzoxazol-2-yl) -7-methyl- [1,4] diazepan-1-yl] - (5-methyl-2- [1,2,3] triazol-2 -yl-phenyl) methanone;

Tshuaj& Cov Khoom Uas Lub Cev:

Tsos: Dawb rau daj ntseg beige khoom

Ntsuas: ≥98.0% +

Qhov ceev: 1.419 g / cm3

Lub Ntsiab Kub: 669.803 ℃ ntawm 760 mmHg

Flash Point: 358.884 ℃

Vapor Siab: 0.0 ± 2.0 mmHg ntawm 25 ℃

Suvorexant, muag nyob hauv kev lag luam tawm npe Belsomra, yog tshuaj rau kev kho mob ntawm insomnia. Nws yog qhov ua tau zoo rau insomnia, tsawg kawg yog plaub lub lis piam thiab muab piv rau cov placebo.

Suvorexant yog xaiv xaiv, dual orexin receptor antagonist ua los ntawm Merck& Co. Nws tau pom zoo rau kev muag khoom los ntawm Asmeskas Cov Khoom Noj thiab Tshuaj (FDA) Lub Yim Hli 13, 2014. Tsoom Fwv Saib Xyuas Kev Tswj Yeeb Tshuaj (DEA) tau muab nws tso rau hauv cov npe tswj hwm raws sij hawm IV tshuaj, vim nws yuav ua rau muaj kev txwv lub cev. dependence los yog dependence kev txheeb ze rau cov tshuaj los yog lwm yam tshuaj nyob hauv lub sij hawm III. Muaj peev xwm ua rau kev xav ntau yam zoo ib yam li zolpidem. Cov tshuaj tau dhau los nyob hauv Nyij Pooj lub Kaum Ib Hlis 2014 thiab Tebchaws Asmeskas hauv Lub Ob Hlis 2015.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: suvorexant cas 1030377-33-3, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: (R) - (7-methyl-1,4-diazepan-1-yl) (5-methyl-2- (2H-1,2,3-triazol-2-yl) phenyl) methanone CAS 1030377-32-2
• Tom ntej: Benzyloxyacetic Acid CAS 30379-55-6